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“Success consists of going from failure to 
failure without loss of enthusiasm.” 
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ABSTRACT 
 
P-cadherin is a cell-cell adhesion molecule and an important mediator of the aggressive 
behavior and metastatic potential of breast cancer cells. This molecule is also a well-
established indicator of poor patient prognosis in breast cancer. Importantly, P-cadherin 
expression promotes stem-like properties to breast cancer cells, such as tumorigenic 
capacity and anoikis resistance, being recognized as a breast cancer stem cell (BCSC) 
marker.  
BCSCs are known to exhibit pro-glycolytic metabolic skills, allowing them to decrease 
oxidative stress, escape anoikis, survive in circulation and increase metastasis 
formation. Disturbing this survival skill by metabolic reprograming would target these 
properties and impact the efficacy of cancer treatment. Recently, we have demonstrated 
that P-cadherin aberrant expression is associated with hypoxic, glycolytic and acidosis 
markers in breast carcinomas, that hypoxia-inducible factor 1 alpha (HIF-1D) stabilization 
increases membrane P-cadherin expression and that P-cadherin enriched cell 
populations show increased glucose transporter 1 (GLUT1) and carbonic anhydrase IX 
(CAIX) expression, as well as high mammosphere forming efficiency. Moreover, 
preliminary data from the group points for the hypothesis that aberrant P-cadherin 
expression might have a role in cellular metabolic reprograming of BCSCs, acting as an 
antioxidant and enhancing cell survival in circulation by promoting anoikis-resistance. 
Thus, the main aim of this work was to evaluate the role of P-cadherin in dichloroacetate 
(DCA) induced metabolic reprograming, a pyruvate dehydrogenase kinase (PDK) 
inhibitor, which promotes the shift from glycolysis to oxidative phosphorylation 
(OXPHOS). Using a panel of human breast cancer cell lines, we demonstrated that P-
cadherin-enriched breast cancer cell lines are more sensitive to DCA. Interestingly, we 
also observed that P-cadherin expression modulates the levels of phosphor pyruvate 
dehydrogenase (pPDH), the inactive form of PDH. On the other hand, DCA also 
decreased the expression of P-cadherin, probably by its effect in pPDH. Interestingly, we 
demonstrate that treatment with DCA, decreases the survival of breast cancer cells, 
mainly in P-cadherin enriched breast cancer cells, being this effect more pronounced in 
anchorage-independent conditions. Finally, P-cadherin downregulation induces an 
increase of mitochondrial reactive oxygen species (ROS) production in triple-negative 
basal-like breast cancer (TN-BLBC) cells, probably being responsible for survival role 
attributed to P-cadherin in breast cancer cells.  
Taking together, our results indicate that P-cadherin enrichment dictates the sensitivity 
of breast cancer cells to DCA-induced metabolic reprogramming, through its role in the 
modulation of pPDH expression in breast cancer cells. Thus, we suggest that P-cadherin 
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might be a valuable biomarker to predict the response to DCA treatment in breast cancer 
patients.  
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RESUMO 
 
A caderina-P é uma molécula de adesão célula-célula e um importante mediador do 
comportamento agressivo e do potencial metastático das células de cancro da mama. 
Esta proteína é também um indicador de mau prognóstico destes tumores. A sua 
expressão promove propriedades estaminais, tais como capacidade tumorigénica e 
resistência a anoikis, sendo reconhecida como um marcador de células estaminais de 
cancro da mama.  
As células estaminais de cancro da mama são conhecidas por apresentarem 
propriedades metabólicas que lhes permitem diminuir o stress oxidativo, escapar à 
anoikis, sobreviver em circulação e aumentar a formação de metástases. Assim, 
destabilizar estas capacidades de sobrevivência através da reprogramação metabólica 
pode aumentar a eficácia do tratamento do cancro. Recentemente, o nosso grupo 
demonstrou que a expressão aberrante de caderina-P está associada a marcadores de 
hipoxia, glicólise e de resistência a acidose, em carcinomas da mama. Mostramos ainda 
que a estabilização do HIF-1α aumenta a expressão membranar de caderina-P e que 
populações de células enriquecidas em caderina-P apresentam uma expressão 
aumentada de GLUT-1 e CAIX, bem como uma elevada capacidade de formação de 
mamosferas. Para além disto, resultados preliminares apontam para a hipótese de que 
esta molécula tem um papel na reprogramação metabólica das células estaminais do 
cancro da mama, atuando como um antioxidante e aumentando a sobrevivência celular 
em circulação através da promoção da resistência à anoikis. 
Assim, o principal objetivo deste trabalho foi avaliar o papel da caderina-P na 
reprogramação metabólica induzida por dicloroacetato (DCA), um inibidor da piruvato 
desidrogenase cinase (PDK), que promove a alteração da glicólise para a fosforilação 
oxidativa. Os nossos resultados mostram, pela primeira vez, que as células enriquecidas 
em caderina-P são mais sensíveis ao DCA e que esta proteína é responsável pela 
modulação dos níveis de pPDH, a forma inativa da piruvato desidrogenase (PDH). Por 
outro lado, observamos também que o DCA diminui a expressão da caderina-P, 
provavelmente devido ao seu efeito na pPDH, e ainda que o tratamento com este 
composto diminui a sobrevivência das células preferencialmente enriquecidas em 
caderina-P, sendo este efeito mais pronunciado em condições independentes de 
ancoragem. Finalmente, o silenciamento da caderina-P induz um aumento da produção 
de espécies reativas de oxigénio (ROS) mitocondriais, sendo este provavelmente 
responsável pelo papel de sobrevivência atribuído à caderina-P em células de cancro 
da mama. 
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Em suma, este trabalho sugere que a expressão de caderina-P pode ser um 
biomarcador da sensibilidade à reprogramação metabólica induzida por DCA, em 
doentes com cancro da mama.  
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CHAPTER I  
INTRODUCTION  
 
1. CANCER METABOLISM 
In the last decade, the interest in cancer metabolism has been highly increasing. 
Oncogenic alterations and the tumor microenvironment were found to contribute for the 
acquisition of distinct metabolic cell behaviors. With all the progress in this subject, the 
cellular reprograming of energy metabolism was recognized as a new hallmark of cancer 
cells [1]. 
 
1.1. WARBURG EFFECT 
Glucose is the major macronutrient that allows energy generation for cellular processes 
through the oxidation of its carbon bonds [2]. Normal cells, in the presence of oxygen, 
rely mainly on mitochondrial oxidative phosphorylation (OXPHOS), in which glucose is 
metabolized into carbon dioxide (CO2) and water by glycolytic pyruvate oxidation in the 
mitochondrial tricarboxylic acid (TCA) cycle [3]. In this process, oxygen is the final 
acceptor of electrons, flowing through the mitochondrial electron transport chain, and 
allowing the end of glucose oxidation and the generation of ATP (adenosine 
triphosphate) [4]. In anaerobic conditions, normal cells readdress pyruvate away from 
the mitochondria, producing considerable amounts of lactate and lower levels of energy 
[5].  
However, it has been shown that, in a cancer context, cells produce considerable large 
amounts of lactate, even in the presence of oxygen, being their metabolism frequently 
referred as “aerobic glycolysis” or “Warburg effect”. This effect was described by Otto 
Warburg in the 1920s, where he hypothesized that cancer cells develop a defect in 
mitochondria leading to an impaired aerobic respiration and a subsequent reliance on 
glycolytic metabolism in order to provide energy [6, 7]. Nevertheless, successive work 
showed a normal mitochondrial function in most cancer cells, suggesting an alternative 
explanation for aerobic glycolysis in these cells [8].  
Aerobic glycolysis is a less efficient process for ATP production in comparison to 
mitochondrial OXPHOS (2 ATP molecules instead of 36 by TCA cycle), which raises the 
question why do cancer cells perform this metabolic shift towards glycolysis. Several 
explanations fit perfectly to answer this question: 1) lactate production from glucose is 
faster than its complete oxidation in the mitochondria, so the fast production of energy 
can be rapidly tuned to support the demand for ATP synthesis by cancer cells; 2) the 
13 
 
Warburg effect functions as an adaptive mechanism to support the biosynthetic 
requirements of proliferative cells, in which increased glucose consumption is used as a 
carbon source for anabolic processes [9]; 3) the Warburg effect is also an advantage for 
tumor progression, since elevated glucose metabolism decreases the tumor 
microenvironment pH through lactate and protons secretion, allowing increased 
invasiveness of the surrounding areas by cancer cells [10, 11]; 4) increased glycolysis 
and OXPHOS impairment is also important in the modulation of reactive oxygen species 
(ROS), interfering directly in tumor cell’s signaling. The homeostatic balance of ROS is 
essential for the appropriate functioning of normal cells. Excessive cellular ROS will 
damage cell membranes, nucleic acids, among others deleterious effects, but insufficient 
ROS will disrupt signaling processes that will benefit cell proliferation. Therefore, the 
Warburg effect causes alterations in mitochondrial redox potential and consequently 
changes in ROS production [2, 12]. 
In highly proliferative cells, such as cancer cells, ATP and NADH (reduced nicotinamide 
adenine dinucleotide) are not the only required products, and glycolysis and TCA do not 
function only for compensating cellular energetic demands. These pathways and their 
intermediate products are deviated to other molecular pathways, such as pentose 
phosphate pathway (PPP), hexosamine synthesis and serine/glycine synthesis 
pathways, in order to provide precursors for the synthesis of building blocks, such as 
lipids, proteins, DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). Furthermore, 
PPP activation has been widely demonstrated in several types of cancer and associated 
with invasion, metastasis, angiogenesis, and resistance to chemo- and radiotherapy [13, 
14]. The increase in flux through the PPP generates abundant reductive power in the 
form of NADPH (reduced nicotinamide adenine dinucleotide phosphate), which in turn 
allows increased ATP production and lipid synthesis, providing protection against 
oxidative damage (Figure 1). Like glucose, glutamine is also a substrate for tumor and 
proliferative cells, being an important mitochondrial substrate that is metabolized over 
glutaminolysis and involved in the protection of cells from oxidant injury, through 
glutathione and mitochondrial phosphate-activated glutaminase enzyme [15].  
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Figure 1. Proliferating cancer cells rely 
mainly on a glycolytic and glutamine-
addicted profile (black arrows and 
orange boxes), instead of 
mitochondrial respiration (grey 
arrows), which is referred to as the 
Warburg effect and glutaminolysis. 
Cancer cells use glucose and glutamine 
as main sources of energy carbon 
precursors. The carbon flux through 
glycolysis and glutaminolysis is increased 
in cancer cells and allows the decrease of 
reactive oxygen species (ROS) levels, as 
well as the production of energy and 
precursor intermediates for feeding the 
pentose phosphate pathway (PPP) and a 
truncated tricarboxylic acid (TCA) cycle 
that further feed carbon intermediates into 
biosynthesis pathways, such as 
nucleotide, lipid and amino acid synthesis, 
that are used for making new cells. 
Adapted from Deblois G & Giguère V, 
Nature Reviews Cancer, 2012 [16]. 
 
 
 
1.2. OXIDATIVE STRESS IN CANCER 
Mitochondria is the main intracellular source of ROS in most tissues, either in 
physiological and pathological conditions. ROS are a highly reactive group of oxygen-
containing molecules, such as superoxide radicals (O2•−), hydrogen peroxide (H2O2), 
hydroxyl radicals (•OH), and singlet oxygen (1O2), being generated as metabolic by-
products by biological systems [17]. At low or moderate concentrations, ROS function as 
signaling molecules, being implicated in different biological processes, such as cell 
adhesion, migration, proliferation, differentiation and survival [18]. An imbalance 
between the production of ROS and the ability of a biological system to detoxify these 
reactive products, leads to an excessive accumulation of ROS and, consequently, to cell 
and tissue damage, being this phenomenon known as oxidative stress [17]. This process 
can affect negatively several cellular structures, such as membranes, lipids, proteins, 
lipoproteins, as well as DNA [19]. Thereby, the maintenance of highly regulated 
mechanisms to control the levels of ROS is essential for normal homeostasis and proper 
response to environmental stimuli. In this context, cells display an antioxidant defensive 
system based mainly on enzymatic components, namely superoxide dismutase (SOD), 
catalase (CAT) and glutathione peroxidase (GPx), in order to protect themselves from 
ROS-induced cellular damage [20]. 
15 
 
 
Cells that undergo aerobic metabolism are subjected to some degree of oxidative stress 
[21]. However, undifferentiated cells such as stem cells, by residing in low oxygen 
tension compartments, maintain slow cycling proliferation, are quiescent, as well as can 
escape from oxidative stress damage associated with oxygenated tissues [22, 23]. 
Therefore, hypoxia induces a metabolic shift that diverge glucose metabolites to 
glycolysis, in order to maintain ATP production and prevent the increase of ROS 
concentration to a toxic level [24]. Accordingly, it has been described a difference in ROS 
levels between progenitor cells and their more mature progeny, which seems to be 
critical for maintaining stem cell function [25]. Thus, in the mammary gland, the luminal 
and the basal/myoepithelial cell layers, were found to present different ROS levels, being 
this difference attributed to variances in their mitochondrial content [26]. In this context, 
normal human basal mammary epithelial cells present low levels of ROS, which seems 
to be maintained by glutathione-dependent systems, while the matching purified luminal 
progenitor cells have higher levels of ROS, several glutathione-independent antioxidants 
and oxidative nucleotide damaging control proteins, and higher rate of oxygen 
consumption [27]. Furthermore, it is known that luminal progenitor cells are more 
resistant to glutathione depletion than basal cells, as well as to H2O2-induced oxidative 
stress and ionizing radiation [27]. Interestingly, mammary epithelial cells coordinate their 
responses to detachment through the increase of the SOD2 antioxidant system, 
decreasing the production of ROS from mitochondrial oxidation and, therefore, escaping 
extracellular matrix (ECM)-detachment cell death [28].  
Similarly, in cancer cells, the Warburg effect causes alterations in mitochondrial redox 
potential, and, subsequently, changes the production of ROS, decreasing the 
concentration of ROS in these cells  [12]. Furthermore, it has been widely described in 
human and murine models, that breast cancer cells presents decreased levels of ROS 
and high antioxidant defenses [26, 29], which besides being advantageous for the 
escape of these cells to oxidative stress induces cell death is also implicated in the 
therapy resistance [30], since ROS are critical mediators of ionizing radiation-induced 
cell death [31]. Accordingly, scarce ROS levels in breast cancer cells have been 
associated with diminished DNA damage in the presence of ionizing irradiation and with 
radio sensitization following the depletion of ROS scavengers [26].  
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1.3. METABOLIC REPROGRAMING IN CARCINOGENESIS  
Normal cells evolve progressively to a neoplastic state through the acquisition of 
successive pathogenic mutations [1]. In a normal epithelium, short diffusion distance 
allows physiological levels of growth factors, substrates and metabolites. However, 
hyperproliferation carries cells away from the basement membrane, increasing the 
diffusion distance, resulting in regional hypoxia. In these conditions, the hypoxia-
inducible factor 1 alpha (HIF-1α) induces the expression of products responsible for 
mediating changes in energy metabolism, pH regulation, angiogenesis, cell survival, cell 
invasion, as well as cell motility, by upregulating anaerobic glycolysis and increasing 
acidosis, to generate the required ATP [32, 33].  
The metabolic plasticity of cancer cells is involved in cancer progression, drug resistance 
as well as in metastasis [34]. Thus, metabolic reprograming offers a wide range of 
potential targets to impair tumor initiation and progression, such as metabolic enzymes 
[35, 36]. Thereby, a metabolic targeting approach can prevent the nutrient supply for 
cancer cells and can also impair bioenergetics, in order to prevent an adaptive response 
to cell stress [36]. Currently, there are several anti-cancer strategies based on metabolic 
addiction of cancer cells, such as 2-deoxyglucose (2-DG), 3-bromopyruvate (3-BrP), and 
ionidamide, which target hexokinase (HK), as well as oxamate, that inhibits lactate 
dehydrogenase A (LDHA) [35], among others (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Targeting glucose metabolism in cancer cells. Key metabolic pathways and control points, 
which may serve as useful targets for cancer therapy, are shown schematically. Glucose enters in the cell 
by glucose transporters, being metabolized by glycolysis to pyruvate in the cytosol. Pyruvate is either 
converted to lactate through the action of lactate dehydrogenase-A (LDH-A), or imported into the 
mitochondrial matrix where it is converted to acetyl coenzyme A (CoA) via pyruvate dehydrogenase (PDH). 
Then acetyl CoA enter the tricarboxylic acid (TCA) cycle. In cancer cells, pyruvate often enters a truncated 
TCA cycle and its metabolites are diverted away from complete oxidation and into various biosynthetic 
pathways (purple arrows). The glycolytic intermediate glucose-6-phosphate can also be diverted into 
nucleotide synthesis pathways through the pentose phosphate shunt. Key enzymes which may be 
particularly promising targets for cancer therapy are shown in blue; drug inhibitors of these enzymes are 
shown in green. Pyruvate dehydrogenase kinase (PDK) suppresses activity of PDH and is itself inhibited by 
dichloroacetate (DCA). TCA enzymes which are known to be mutated in cancer are shown in red: IDH2 
(isocitrate dehydrogenase 2), SDH (succinate dehydrogenase), and FH (fumarate hydratase). Adapted from 
Fogg et al., 2011 [37]. 
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A key branching point in the glycolytic pathway is the production of pyruvate [38]. Under 
normoxia, the pyruvate dehydrogenase (PDH) complex (PDC) governs the conversion 
of pyruvate into acetyl coenzyme A (CoA) through oxidative decarboxylation, controlling 
the flow of metabolites from glycolysis to the TCA cycle and, subsequently, the 
generation of ATP by mitochondria. This PDC activity is regulated by pyruvate 
dehydrogenase kinase (PDK), which phosphorylates and inactivates PDH [39]. 
Interestingly, it has been demonstrated that this cancer-specific metabolic remodeling 
can be reversed by dichloroacetate (DCA), a mitochondrial-targeting small molecule that 
inhibits PDK activity [38, 40, 41]. Thus, DCA can switch cancer cell metabolism from 
glycolysis to mitochondrial OXPHOS [38, 42] (Figure 3). Several studies have been 
demonstrating the potential role of DCA as an approach in cancer treatment, being 
already used in clinical trials  [38, 43-45]. 
 
 
 
   
 
 
 
 
 
Figure 3. DCA inhibits the mitochondrial enzyme PDK, maintaining PDH in its active 
unphosphorylated state and facilitating the aerobic oxidation of glucose. PDH, located in the 
mitochondrial matrix, in its active unphosphorylated state mediates acetyl coenzyme-A formation from 
pyruvate, which feeds the electron transport chain responsible for ATP synthesis and oxygen consumption. 
Phosphorylation of PDH by PDK generates its inactive phosphorylated state. DCA-mediated inhibition of 
PDK renders most of PDH in the active form and then pyruvate metabolism switches towards glucose 
oxidation to CO2 in the mitochondria. Adapted from Miquel E. et al., 2012 [46]. 
 
 
 
1.4. METABOLIC ALTERATIONS IN BREAST CANCER 
An increasing body of evidence have demonstrated that metabolic reprograming is 
fundamental for breast cancer initiation and progression [35]. In this context, Lu et al. 
proposed that metabolite alterations in several pathways, such as glycolysis, TCA and 
PPP, follows tumor progression in a mouse model of breast cancer [47]. Moreover, Shaw 
et al. demonstrated that there is a decrease in OXPHOS metabolism with breast cancer 
progression, with a decrease of cellular oxygen consumption rate (OCR) and an 
increased aggressiveness of breast cancer cells [48]. Also, comprehensive metabolic 
profiles identified metabolite deregulation in invasive breast carcinomas compared with 
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normal breast tissue, implicating changes in metabolic pathways during breast cancer 
progression [49]. Still, Budczies et al. identified key metabolic markers that separate 
cancer from normal tissue with high sensitivity and specificity [49].  
Actually, analyzing the immunohistochemical expression of HIF-1α, glucose transporter 
1 (GLUT1) and carbonic anhydrase IX (CAIX) in a histological model of breast cancer 
progression, Chen et al. demonstrated that there is as a powerful adaptive advantage 
associated to an aggressive phenotype in breast carcinomas [50].  
A few years ago, gene expression analysis have improved the cellular and molecular 
understanding of breast cancer by identifying distinct molecular subtypes with different 
transcriptional signatures and clinical outcomes [51]. The basal-like breast cancer 
(BLBC) subtype has drawn the attention of the scientific community due to the lack of 
targets to therapy, since they are characterized by a triple negative phenotype, lacking 
the expression of hormone receptors (ER and PgR, estrogen and progesterone receptor, 
respectively), and human epidermal growth factor receptor 2 (HER2) [52]. Interestingly, 
this aggressive molecular subtype of breast carcinomas presents an increased response 
to hypoxia, as well as a predominant glycolytic metabolism. Several reports have 
demonstrated a differential expression of proteins induced by hypoxia and the 
development of a glycolytic/acid resistant phenotype in BLBC [53-55]. Kim et al. 
evaluated the metabolic phenotype of triple-negative breast cancer (TNBC), based on 
the immunohistochemical expression profiles of GLUT1 and CAIX, and observed a 
Warburg molecular phenotype in these tumors [56]. Accordingly, Doyen and co-workers 
also described a classical Warburg metabolism in TNBC, with high glucose uptake and 
increased lactate secretion, expressing glycolytic and hypoxic markers [57]. Still, several 
other authors showed that GLUT1, CAIX, monocarboxylate transporter 1 (MCT1) and 
cluster of differentiation (CD) 147 are differentially expressed in BLBC, as well as are 
associated to the absence of hormone receptors and expression of key basal markers, 
such as cytokeratin (CK) 5, EGFR (epidermal growth factor receptor), CK14 and 
vimentin. Moreover, these glycolytic markers were found to be associated with 
aggressive clinic-pathological characteristics in primary invasive breast carcinomas, 
such as high proliferation rates, high histological grade and poor patient’s survival [53-
55, 58, 59].  
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2.  CANCER STEM CELLS 
Over the years, increasingly evidence for the existence of cancer stem cells (CSCs), or 
tumor-initiating cells (TICs), has supported the implication of these cells in breast cancer 
development. Accordingly, there are some established markers to isolate these cancer 
cells that are highly tumorigenic, with high propensity to metastasize and resistant to 
therapeutic treatments [60]. 
 
2.1. DEFINITION AND CHARACTERIZATION  
Tumor cells have high proliferative capacity, phenotypic plasticity and aberrant 
differentiation. Actually, stem cells and tumor cells share numerous properties and 
characteristics, namely self-renewal capacity, the reliance on similar signaling pathways, 
as well as biomarkers [61]. Stem cells are present in many different somatic tissues and 
are characterized by their self-renewal ability, the capacity to generate multiple cell 
lineages, as well as by the potential for sustained proliferation [62, 63]. These processes 
occur in a highly regulated manner, under the control of specific molecular machinery 
and influence of the surrounding microenvironment [61, 64].  
The CSC hypothesis proposes that tumors have a hierarchical organization, being a 
small subpopulation of tumorigenic cells responsible for tumor formation and progression 
[65]. These cells with stem-like properties, or CSCs, are defined as a distinct population 
of cancer-initiating cells with the ability of self-renewal and to generate both further CSCs 
and more differentiated cancer cells [65]. In this way, CSCs are thought to originate the 
bulk of the primary tumor and to contribute to tumor heterogeneity [65]. Despite CSCs 
share numerous properties with normal stem cells, it is still not clear their origin [66, 67].  
Until now, CSCs have been isolated from several human tumors, including leukemia [68], 
breast [63], melanoma [69] and colon [70], and the presence of these tumor cells subsets 
is strongly correlated with tumor recurrence and treatment failure [71]. Nevertheless, the 
isolation and characterization of these cells have been a major challenge in science [72]. 
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2.2. BREAST CANCER STEM CELLS 
In breast cancer, CSCs are designated breast cancer stem cells (BCSCs) and share 
important properties with mammary stem cells, such as the ability to proliferate and resist 
to radiation- and chemotherapy-induced cell death, allowing them to survive and to cause 
tumor recurrence [29, 73]. Although there is still not an universal criteria to characterize 
and identify BCSCs, several phenotypes and markers have been described to be able 
to identify and isolate these cells, such as CD44+ CD24- phenotype or aldehyde 
dehydrogenase-1 (ALDH1) activity [60, 74-76]. The current gold standard method for 
assessing BCSCs activity is the ability of these cells to re-grow tumors in immuno-
compromised mice, after being isolated by fluorescence activated cell sorting (FACS), 
using antibodies to specific cell surface markers or intracellular enzymes, such as ALDH 
(ADEFLUOR assay) [77]. Moreover, in non-adherent conditions, BCSCs, such as 
mammary stem and progenitor cells, are able to proliferate in an undifferentiated state, 
while differentiated cells die by anoikis. Thus, taking advantage of this anoikis resistance 
ability of BCSC, the Mammosphere Forming Efficiency (MFE) assay is also used to 
identify cancer cell populations enriched for stem-like properties [78].  
 
2.3. BREAST CANCER STEM CELL’S METABOLISM 
CSCs seem to adapt their metabolism to microenvironmental changes by conveniently 
shifting energy production between pathways or by acquiring intermediate metabolic 
phenotypes [79]. Therefore, emerging data have explored the metabolism of CSCs, 
revealing that these cells have a distinctive metabolic phenotype compared with the bulk 
of the tumor. However, there is still not a consensus about the metabolic behavior of 
BCSCs (Table 1).  
Several authors claim that BCSCs have an increased glycolytic phenotype, which seems 
to be linked to a decrease in mitochondrial oxidative metabolism. In this context, Feng et 
al. demonstrated that mouse and human BCSCs present a more glycolytic phenotype 
compared with their differentiated progeny. These authors found that BCSCs present a 
higher ratio of lactate production to oxygen consumption, higher glucose consumption, 
as well as fewer and less active mitochondria than non-BCSCs [80]. Also, Ciavardelli et 
al. showed that BCSCs shift from OXPHOS to glycolysis, presenting increased 
expression of key enzymes of anaerobic metabolism, namely pyruvate kinase muscle 
isozyme 2 (PKM2) isoform, LDH and G6PD (glucose-6-phosphate dehydrogenase), as 
well as increased antioxidant defense systems [81]. Furthermore, Gammon et al. 
demonstrated that BCSCs, with epithelial-mesenchymal transition (EMT) characteristics, 
present high levels of HIF-1α, decreased mitochondrial mass and membrane potential, 
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consume less oxygen and present lower levels of ROS [82]. Still, Gordon et al. showed 
that BCSCs have the ability to adapt to microenvironment stress, such as starvation and 
hypoxia, by upregulating glucose transporters and switching to a more glycolytic 
phenotype to outcompete with their differentiated counterparts [83]. 
In contrast, other authors claim that BCSCs present increased OXPHOS characteristics 
and behavior. Vlashi et al. demonstrated that BCSCs rely mainly on mitochondrial 
oxidative metabolism, while the more differentiated progeny displays a more glycolytic 
phenotype [84]. Similarly, De Luca et al. also showed that BCSCs obtain energy mainly 
by OXPHOS and that mitochondrial biogenesis is required for anchorage-independent 
survival and propagation of stem-like cancer cells [85]. Also, Farnie et al. hypothesized 
that enhanced mitochondrial function could be partially responsible for chemo-resistance 
in BCSCs, since increased mitochondrial function confers a stem-like phenotype [86]. 
Accordingly, Lamb et al. claims that BCSCs present an increased mitochondrial mass 
and mitochondrial functional activity. They demonstrated that mammospheres are 
enriched for mitochondrial-related enzymes, as well as for proteins involved in 
mitochondrial biogenesis, proposing that increased mitochondrial biogenesis and 
decreased mitochondrial degradation are responsible for the accumulation of 
mitochondrial mass in BCSCs [87, 88]. Furthermore, the same authors also propose that 
mitochondrial mass could be a metabolic biomarker for anabolic BCSCs [89].  
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Table 1. Summary of described metabolic behavior of BCSC.  
 
 BCSC isolation Approach Drug Reference 
G
ly
co
ly
tic
 
Sort CD24-/low cells within the 
sphere culture 
Proteomic and targeted 
metabolomic analysis 2-DG 
Ciavardelli et al., 
2014 [81] 
Sort CD49fhighEpcamlow, 
CD49flowEpcamhigh cells by 
FACS  
Transcriptome profiling using 
RNA-Sequencing - 
Feng et al., 2014 
[80] 
Sort CD44highESAlow cells by 
FACS 
Differences in the patterns of 
oxygen metabolism of sub-
fractions of tumor cells 
- Gammon et al., 2013 [82] 
From invasive carcinomas via 
FACS subpopulations 
expressing CD49fhighCD24low, 
CD49fhighCD24high, 
CD49flowCD24high and 
CD49flowCD24low 
Gene expression signatures 
of breast cancer stem and 
progenitor cells 
- Gordon et al., 2015 [83] 
O
XP
H
O
S 
MFE 
Quantitative proteomics 
analysis to identify 
mitochondrial therapeutic 
targets 
- Lamb et al., 2014 [87] 
Sort BCSCs with low 
proteasome activity using 
FACS 
Metabolic requirements of 
BCSCs and differentiated 
progeny 
- Vlashi et al., 2014 [84] 
MFE with pre-treatment of 
monolayers with XCT790 
Mitochondrial biogenesis as a 
target to impair CSCs 
propagation 
XCT790 De Luca et al., 2015 [85] 
MitoTracker Deep-Red 
staining to metabolically 
fractionate cells into mito-low 
and mito-high subpopulations 
by flow-cytometry 
Therapeutic targeting of 
chemo-resistant CSCs - 
Farnie et al., 
2015 [86] 
MFE with previous 
fractionated GFP-high and 
GFP-low groups treated with 
MST-312 at day 0 
hTERT-promoter-eGFP-
reporter system to identify 
and purify a subpopulation of 
MCF-7 cells, with high hTERT 
transcriptional activity by 
FACS 
MST-312, a 
telomerase 
inhibitor 
Lamb et al., 2015 
[88] 
MFE of sorted MCF-7 cells for 
MitoTracker Deep-Red 
Proteomic analysis of a 
humanized model of mouse 
mammary tumor virus 
- Lamb et al., 2015 [89] 
MFE 
Comparison between the 
proteome of MCF-7 cell 
monolayers and MCF-7-
derived mammospheres 
using proteomic analysis 
- Lamb et al., 2015 [90] 
MFE Mitochondrial biogenesis as a selective target of CSCs Antibiotics 
Lamb et al., 2015 
[91] 
MFE with pre-treatment of 
monolayers with Atovaquone 
Mitochondrial complex III and 
OXPHOS as a target to 
eradicate CSCs 
Atovaquone Fiorillo et al., 2016 [92] 
MFE Mitochondrial complex I as a target to kill BCSCs Metformin 
Hirsch et al., 
2012 [93] 
Epcam: Epithelial cell adhesion molecule; ESA: epithelial surface antigen; GFP: green fluorescent protein; hTERT: Human 
telomerase reverse transcriptase. 
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3. P-CADHERIN: A CELL-CELL ADHESION MOLECULE 
Classical cadherins are a family of molecules with important functions in cell-cell 
adhesion, tissue morphogenesis and cancer [94]. P-cadherin (placental cadherin) is one 
of the four classical cadherins (E-cadherin (epithelial), N-cadherin (neural) and R-
cadherin (retinal)) [94], being the third to be identified and characterized [95]. 
 
3.1. STRUCTURE AND FUNCTION 
CDH3, the gene encoding P-cadherin, share 66% of homology with the far more well 
characterized CDH1 (the gene that encodes E-cadherin), being mapped in chromosome 
16q22.1, a region that contains a cluster of several cadherin genes [96]. Specifically, 
CDH3 gene is composed by 16 exons and exhibits a high degree of conservation in 
intron positions and a large intron after exon 2 [97].  
P-cadherin has a molecular weight of 118 kDa and a similar molecular structure to that 
of classical cadherins [98]. The function and strength of P-cadherin-mediated adhesion 
depends on its dynamic association with catenins, through the cadherin-catenin complex 
[94, 98]. The cytoplasmic tail of P-cadherin contains two main domains: the catenin-
binding domain (CBD), essential for cadherin function, and the juxtamembrane domain 
(JMD), which has been suggested to play a critical role in allowing cells to relocate [99] 
(Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic representation of the structure of the P-cadherin adhesive junction. Lateral 
clustering of P-cadherin molecules is required to form stable cell-to-cell contacts in BT20 breast cancer cells. 
In the intercellular space, P-cadherin extracellular domains interact with P-cadherin extracellular domains of 
adjacent cells to mediate cell-cell adhesion. Intra-cellular catenins bind to the cytoplasmic tail of P-cadherin. 
p120-ctn binds the cadherin tail at the juxtamembrane domain (JMD), whereas β-catenin binds to the distal 
catenin binding domain (CBD). α-catenin associates with β-catenin and is directly linked to the actin 
cytoskeleton. The lower panel represents the genomic structure of CDH3/P-cadherin gene, which is 
constituted by 16 exons: the extracellular part of P-cadherin is encoded by 10 exons (exons 4-13), whereas 
the transmembrane and intracellular domains are determined only by the information included in the last 3 
exons (exons 14-16). Adapted from Albergaria et al., 2011 [94]. 
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3.2. ROLE IN STEMNESS AND IN CELL DIFFERENTIATION 
P-cadherin has a crucial role in maintain the structural integrity of epithelial tissues. 
Moreover, it is accepted that this molecule participates in embryonic development and 
that it contributes to the biology of stem cells of the normal mammary gland and the hair 
follicle. Furthermore, this adhesion molecule is considered a biomarker for the isolation 
and characterization of stem cells, such as in human embryonic stem cell (hESC), as 
well as important mediator of stem cell activity through the modulation of signaling 
pathways [94, 100]. 
In the normal mammary gland, P-cadherin is restricted to the basal myoepithelial layer, 
contributing to the supra basal stem cell niche [101]. During normal breast development, 
P-cadherin has a critical role in the ductal mammary branching, being expressed by 
myoepithelial precursor cells, the cap cells, at the terminal end buds [102]. Moreover, P-
cadherin function has been clarified by P-cadherin inactivation studies performed in 
mice. In this context, Radice et al. demonstrated that normal mammopoiesis is affect by 
P-cadherin deletion, since CDH3-null female mice, in the virgin state, present precocious 
mammary gland differentiation, breast hyperplasia, as well as dysplasia with age [103]. 
Several studies have elucidated that P-cadherin expression is crucial to the maintenance 
of normal breast epithelial architecture. Chanson et al., by using an antibody that 
specifically antagonizes P-cadherin cell-cell interactions, demonstrated that the 
migration of mammary myoepithelial cells was compromised [104]. Furthermore, 
Nguyen-Ngoc et al. showed that P-cadherin loss causes precocious branching 
morphogenesis in matrigel, showing the importance of P-cadherin in the maintenance of 
normal breast epithelial architecture [105]. Taking together, these findings demonstrate 
that P-cadherin expression and signaling are essential for limiting the growth of the 
mature luminal epithelial cells, as well as for the maintenance of an undifferentiated state 
of the normal mammary gland, pointing to the role of P-cadherin as a putative stem cell 
marker. 
 
3.3. P-CADHERIN IN BREAST CANCER 
Due to their importance in normal development and tissue architecture, alterations in 
classical cadherins are implicated in disease [98]. Mutations in CDH3 gene, resulting in 
abnormal P-cadherin expression, have been recognized as being responsible for 
congenital hypotrichosis with juvenile macular dystrophy, a rare autosomal recessive 
disorder characterized by short sparse scalp hair at birth and progressive macular retinal 
degeneration that leads to early blindness [106, 107]. Moreover, alterations in P-cadherin 
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expression have been widely associated with several solid tumors, including breast, 
prostate, colon, pancreatic and bladder cancer [98]. 
Particularly, in breast cancer, P-cadherin was found to be aberrantly expressed in 25% 
of ductal carcinomas in situ (DCIS), as well as in 20% to 40% of invasive breast 
carcinomas [98, 108-110]. P-cadherin is a marker of poor prognosis in breast cancer, 
associated with short-term overall and disease-free survival, as well as with distant and 
locoregional relapse-free interval [111-115]. P-cadherin is differentially expressed in poor 
prognosis BLBC [98]. Accordingly, its expression has been positively associated with 
poorly differentiated and high histological grade tumors, as well as with established 
markers of poor prognosis, such as ki-67, EGFR, CK 5/6 and CK14, and negatively 
associated with age at diagnosis, hormonal receptors (ER and PgR), and B-cell 
lymphoma 2 (Bcl-2) expression [82, 112-114]. Moreover, our group has demonstrated 
that P-cadherin expression shows higher sensitivity to distinguish the basal phenotype 
of breast carcinomas, being a reliable marker to be used in the daily practice of breast 
pathology laboratories for the identification these tumors [116].  
We have also demonstrated that P-cadherin overexpression promotes cell motility, 
migration and invasion capacity and influences cell shape and cell polarity [117, 118]. 
Additionally, we observed that P-cadherin functional role is dependent on E-cadherin 
cellular context. Using in vitro and in vivo assays, as well as human primary breast cancer 
samples, we showed that the co-expression of E- and P-cadherin significantly enhanced 
tumor growth, is correlated with high histological grade, biologically aggressive behavior 
and with poor patient survival [119]. Taking together, targeting P-cadherin in breast 
cancer may be a good therapeutic approach, since normal associated counterparts 
exhibit low expression levels of this adhesion molecule [120].  
 
3.4. P-CADHERIN AS A BREAST CANCER STEM CELL MARKER  
Due to the high breast cancer heterogeneity, the definition of a single phenotype for 
BCSCs is a challenging task. The aggressiveness and the lack of target therapeutic 
approaches to BLBC has driven the attention to the need of better defining the CSC 
phenotype for this poor-prognosis breast carcinomas [121]. It has been reported that the 
luminal progenitor cell of the normal mammary gland hierarchy is the cell of origin for 
BLBC, since mutations in BRCA1 (breast cancer susceptibility gene 1), a known 
suppressor of CDH3 gene [122], was able to induce the formation of a breast carcinoma 
with basal phenotype [121].  
Recently, our group has proposed P-cadherin as a BCSC marker and a valuable target 
to define the CSC phenotype and the cell of origin of BLBC [101]. We demonstrated that 
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P-cadherin expression is able to promote stem-like properties and is associated with the 
expression of CSC markers, such as CD44, CD49f and ALDH1 [101]. In addition, cell 
populations depleted for P-cadherin expression exhibited decreased in vitro self-renewal 
ability, lower capacity to grow colonies in 3D cultures and reduced tumorigenicity in nude 
mice [101]. Furthermore, P-cadherin expression is fundamental for the adhesion of 
cancer cells to ECM substrates, a critical step for metastatic dissemination. We 
demonstrated that its inhibition caused a significant decreased adhesion of breast cancer 
cells to the basement membrane substrate laminin and a major reduction in the 
expression of the laminin receptor α6β4 integrin [123]. The expression of this 
heterodimer is needed for the invasive capacity and increased MFE induced by P-
cadherin expression, which might explain the stem cell and invasive properties induced 
by this protein in breast cancer cells [123]. 
BCSCs are able to survive and persist in the tumor, being responsible for recurrence of 
the disease [29, 73]. Remarkably, P-cadherin is considered a survival factor in breast 
cancer cells, since decreased P-cadherin expression increases breast cancer cell death 
in a caspase-dependent mechanism, as well as it promotes anoikis resistance, allowing 
cells to survive in anchorage-independent conditions [101, 119]. Still, this molecule 
confers resistance to radiation, since P-cadherin-enriched breast cancer cell population 
showed increased ability to survive in anchorage-independent conditions when 
irradiated, in comparison with P-cadherin depleted cells [124]. 
 
3.5. P-CADHERIN AND CANCER CELL METABOLISM 
P-cadherin promotes stem-like properties to breast cancer cells and is recognized as a 
BCSC marker [101]. Although there is still no consensus, several authors claim that 
BCSCs exhibit pro-glycolytic metabolic skills, allowing them to decrease oxidative stress, 
being able to escape anoikis, survive in circulation and increase metastasis formation 
[125]. Interestingly, and in agreement with the reported glycolytic behavior of BLBC, we 
have recently showed that the expression of this basal epithelial marker P-cadherin 
associates with breast cancer cell populations harboring a glycolytic and acid-resistant 
phenotype, being significantly associated with the expression of HIF-1α, GLUT1, CAIX, 
MCT1 and CD147 in human breast carcinomas [125]. We also showed that P-cadherin 
expression is modulated by hypoxia in a time dependent manner through HIF-1α 
stabilization. Moreover, we observed that P-cadherin-enriched breast cancer cells exhibit 
increased GLUT1 and CAIX expression and that these cells comprise high MFE, 
suggesting that P-cadherin overexpressing BCSCs are more likely to exhibit increased 
glycolysis and to survive to metabolic-driven pH alterations [125]. Furthermore, 
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unpublished data from our group shows that P-cadherin silencing was able to decrease 
the extracellular acidification rate, as well as to modulate cellular ATP content of breast 
cancer cells. Still, we were also able to demonstrate that P-cadherin expression is 
associated with the production of low ROS levels, by inducing the upregulation of ROS 
scavenging systems, such as SOD1 and SOD2. 
Taking together, we believe that this glycolytic and antioxidant role mediated by P-
cadherin expression in breast cancer cells is likely to impact their ability to invade the 
surrounding tissue, to survive in circulation and to promote metastasis.  
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CHAPTER II 
RATIONAL AND AIMS 
 
P-cadherin expression promotes stem-like properties in breast cancer cells, such as 
tumorigenic capacity and anoikis resistance, being recognized as a BCSC marker [71]. 
BCSCs are known to exhibit pro-glycolytic metabolic skills, allowing them to decrease 
oxidative stress, being able to escape anoikis, survive in circulation and increase 
metastasis formation. Disturbing this survival skill by metabolic reprograming would 
target these properties and impact the efficacy of cancer treatment. Recently, we have 
demonstrated that P-cadherin-enriched populations are more likely to present a hypoxic, 
as well as glycolytic and acid-resistant phenotype [125]. Moreover, preliminary data from 
the group points for the hypothesis that aberrant P-cadherin expression might have a 
role in cellular metabolic reprograming of BCSCs, acting as an antioxidant and 
enhancing cell survival in circulation by promoting anoikis-resistance. Despite the recent 
implications of P-cadherin expression in metabolic behavior of breast cancer cells, 
nothing is known about the role of this basal epithelial marker in the sensitization of 
breast cancer cells to anoikis by metabolism reprograming.  
 
Main Aim 
The main aim of this work was to analyze the sensitivity of P-cadherin-enriched breast 
cancer cells to anoikis by in vitro metabolic reprograming using DCA. 
 
Specific Aims 
Using a panel of human breast cancer cell lines, the studies were performed in order to 
address the following aims: 
 
TASK 1) To predict the association between CDH3 expression and the expression of 
the DCA molecular targets in breast cancer, using bioinformatic predictive tools. 
 
TASK 2) In vitro analysis of the P-cadherin role in metabolic reprograming induced by 
DCA in breast cancer cells, using two-dimensional (2D) monolayer, as well as 
anchorage-independent culture conditions. 
 
TASK 3) Evaluation of the effect of P-cadherin expression in the modulation of 
oxidative stress in breast cancer cells. 
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CHAPTER III 
MATERIALS AND METHODS 
 
This chapter describes the materials and methods used for all the data presented in the 
results section. 
 
MATERIALS 
Cell Culture 
Human breast cancer cell lines were obtained as follows: BT20, MDA-MB-468 and MCF-
10A were acquired from American Type Culture Collection (Manassas, VA, USA), 
SUM149 was kindly provided by Dr. Stephen Ethier (University of Michigan, USA), and 
MCF-7/Az was kindly given by Prof. Marc Mareel (Ghent University, Belgium). MCF-7/Az 
cell line was retrovirally stable transduced to encode P-cadherin (MCF-7/Az.P-cadherin 
cell line), as described earlier by the group [126]. MCF-7/Az.Mock cell line, encoding only 
EGFP, was used as a control. Cells were routinely maintained at 37°C and 5% CO2 in 
the following media (Invitrogen Ltd, UK): DMEM for BT20 and MDA-MB-468, and 50% 
DMEM/50% Ham-F12 for SUM149, MCF-10A and MCF-7/Az. In BT20, MDA-MB-468 
and MCF-7/Az cell lines the media contained 10% heat-inactivated fetal bovine serum 
(FBS, Greiner bio-one, Belgium) and in SUM149 cell line, media was supplemented with 
5% FBS, 5µg/ml of insulin and 1µg/ml of hydrocortisone (Sigma-Aldrich, USA). MCF-
10A media was supplemented with 20ng/ml of epidermal growth factor (EGF, Sigma-
Aldrich, USA), 0.5mg/ml of hydrocortisone, 100ng/ml of cholera toxin (Sigma-Aldrich, 
USA), 10μg/ml of insulin and 5% horse serum (Invitrogen). All media were supplemented 
with 100 IU/ml penicillin and 100 mg/ml streptomycin (Invitrogen Ltd, UK). 
 
Primary Antibodies and Reagents 
For Western blot, we used the following primary anti-human antibodies against: P-
cadherin (clone 56, BD Transduction Biosciences, USA; diluted 1:500), phospho PDH 
(pPDH) at serine (Ser) residue 293 (ab177461, Abcam, UK; diluted 1:1000), total PDH 
(tPDH) (ab197956, Abcam, USA; diluted 1:3000) and 70 kDa heat shock protein 
(HSP70), as housekeeping (sc-7298, Santa Cruz; diluted 1:2000). 
Presto blue reagent (Invitrogen, UK) was used to evaluate the viability of cells. Metabolic 
reprograming was induced by DCA (Sigma-Aldrich, USA), and MitoSOX™ Red reagent 
(ThermoFisher Scientific, UK) was used to measure mitochondrial ROS levels by 
immunofluorescence analysis. 
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METHODS  
Bioinformatic analysis using public available gene expression databases 
of human breast cancer 
To study the possible association between PDK, PDHA1 and CDH3 genes, we have 
used The Cancer Genome Atlas (TCGA), as well as the Cancer Cell Line Encyclopedia 
(CCLE) online databases, in breast cancer samples and cell lines, respectively. 
 
Cell viability assay 
Cells were plated in a 96-wells plate and treated with DCA in a daily basis. After 24h of 
treatment cells were washed with phosphate buffered saline (PBS) 1x and presto blue 
reagent was added at 1:20 diluted in culture medium. Cells were incubated at 37˚C, 5% 
CO2 for 35 minutes and the fluorescence was read at 50% sensitivity top reading on the 
following wave-length (λ): λexcitation =560nm and λemission=590nm. 
 
Protein extraction and western blot analysis 
Protein lysates were prepared from cells using catenin lysis buffer [1% (v/v) Triton X- 
100 and 1% (v/v) NP-40 (Sigma-Aldrich, USA) in PBS] supplemented with 1:7 protease 
inhibitor cocktail (Roche Diagnostics GmbH, Germany, 11836170001) and with 1:100 
phosphatase inhibitor cocktail 3 (Sigma-Aldrich, USA, P0044) for 10 min, at 4°C. Cell 
lysates were mixed with a vortex and centrifuged at 14000 rpm at 4°C, during 10 min. 
Supernatants were collected and protein concentration was determined using the 
Bradford assay (Bio-Rad Protein Assay kit, USA). Proteins were dissolved in sample 
buffer [Laemmli with 5% (v/v) 2-β-mercaptoethanol and 5% (v/v) bromophenol blue] and 
boiled for 10 min at 95°C. Samples were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and proteins were transferred into 
nitrocellulose membranes [Amersham Hybond enhanced chemiluminescence (ECL)]. 
For immunostaining, membranes were blocked for 1 hour with 5% (w/v) non-fat dry milk 
in PBS containing 0.5% (v/v) Tween20 and incubated overnight at 4°C with anti-P-
cadherin, anti-pPDH, anti-tPDH and anti-HSP70. After washed with PBS-Tween20, 
membranes were incubated with horseradish peroxidase (HRP)-conjugated anti-mouse, 
or rabbit secondary antibodies (Santa Cruz Biotechnologies, USA) diluted 1:2000 for 1 
hour. Proteins were then detected using ECL reagent (Amersham, USA) as a substrate. 
Quantity One software (Bio-Rad, USA) was used for quantification of the differences in 
protein expression comparing with HSP70 expression. 
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siRNA transfection 
Gene silencing was performed with validated small interfering ribonucleic acids (siRNA), 
specific for CDH3 (50nM, Hs_CDH3_6, Qiagen, USA). Transfections were carried out 
using Lipofectamine 2000 (Invitrogen, UK), according to manufacturer’s recommended 
procedures. After incubation for 5 minutes, the siRNA and Lipofectamine 2000 solutions 
were mixed, incubated for additional 20 minutes and added to cell culture medium. A 
scrambled siRNA sequence, with no homology to any gene, was used as a negative 
control (Qiagen, USA). 
 
Mammosphere Forming Efficiency (MFE) assay 
After 24 hours of the siRNA transfection, cells were treated with DCA and incubated for 
24 hours at 37°C, 5% (v/v) CO2. After incubation, cells were enzymatically harvested and 
manually disaggregated to form a single-cell suspension and resuspended in cold PBS. 
Cells were plated at 500/cm2 in non-adherent culture conditions, in 6-well plates coated 
with 1.2% poly(2-hydroxyethylmethacrylate)/95% ethanol (Sigma-Aldrich, USA) and 
allowed to grow for 5 days, in DMEM/F12 containing B27 supplement (Invitrogen, UK), 
500ng/ml of hydrocortisone, 40ng/ml insulin, 20ng/ml EGF in a humidified incubator at 
37°C and 5% (v/v) CO2. MFE was calculated as the number of mammospheres (≥50μm) 
formed divided by the number of cells plated, being expressed as a percentage. 
 
MitoSOX™ Red immunofluorescence assay 
BT20 cells were cultured on glass coverslips and 24 hours later they were transfected 
with control and CDH3 siRNA. Fresh media was added for 30 minutes before the 
experiment. Cells were washed with Hank’s balanced salt solution (HBSS) and incubated 
with 1,5µM of MitoSOX™ Red for 45 minutes. After that, cells were washed with PBS, 
fixed with 4% paraformaldehyde (20 minutes) and washed twice with PBS, at room 
temperature. Each sample was mounted with Vectashield (Vector Laboratories, Inc, 
Burlingame, CA) containing 4,6-diamidine-2-phenylindolendihydrochrolide (DAPI) and 
visualized with Leica SP5 confocal microscope (Leica Microsystems GmbH, Germany).  
 
Statistical analysis 
Results are representative of three independent experiments. Quantifications are 
expressed as mean ± SEM (standard error of the mean) of the biological replicates 
considered. Statistical analyses were performed using Office Excel 2016 (Microsoft 
Corporation, Reading, UK). All statistical tests were two-sided and considered as 
significant when P value was lower than 0.05. 
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CHAPTER IV 
RESULTS  
 
I. BIOINFORMATICS ANALYSIS OF THE LINK BETWEEN P-CADHERIN 
EXPRESSION AND THE EXPRESSION OF DCA MOLECULAR TARGETS IN 
BREAST CANCER 
Since PDK is a well-established target of DCA, the aim of this first part of the work was 
to search for evidences that would support and predict the link between the response of 
P-cadherin positive breast cancer cells to DCA treatment, through the association 
between DCA molecular targets (PDK and PDH) and CDH3 expression. Therefore, in 
order to achieve this purpose, we examined online available gene expression databases. 
 
CDH3 expression is correlated with PDK1 and PDHA1 expression in breast 
cancer 
Using online TCGA database, we analyzed whether CDH3 expression is correlated with 
the DCA molecular effectors, such as PDK (1-4) and PDHA1 genes in breast cancer 
samples (Figure 5). 
Interestingly, we observed that CDH3 is positively correlated with PDK1 (ρ=0.408) 
(Figure 5A) and PDHA1 mRNA (messenger RNA) expression (ρ=0.335) (Figure 5E). 
However, no correlation was found between CDH3 and the other PDK isoforms, namely 
PDK2 (ρ=-0.235) (Figure 5B), PDK3 (ρ=0.210) (Figure 5C) and PDK4 (ρ=-0.083) 
(Figure 5D).  
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Figure 5. Correlation between CDH3 and PDK isoforms and PDHA1 genes in breast cancer. CDH3 is 
positively correlated with A) PDK1 (ρ=0.408) and E) PDHA1 (ρ=0.335). However, no correlation was found 
between CDH3 and B) PDK2 (ρ=-0.235), C) PDK3 (ρ=0.210) or D) PDK4 (ρ=-0.083) in this type of cancer. 
Adapted from TCGA online gene database. (ρ: Pearson correlation coefficient) 
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II. IN VITRO ANALYSIS OF P-CADHERIN ROLE IN METABOLIC 
REPROGRAMING INDUCED BY DCA IN BREAST CANCER CELLS 
The evidence found on the association between DCA molecular targets and CDH3 
expression using bioinformatic analysis, led us to go further on the role of this adhesion 
molecule in the DCA induced effects in breast cancer cells.  
 
IIa) Analysis of the sensitivity of breast cancer cells to DCA-induced 
metabolic reprograming in 2D monolayer culture 
In order to analyze the sensitivity of breast cancer cells to DCA, we treated different 
breast cancer cell lines with a range of DCA concentrations (0-100mM), during 24 or 48 
hours. Using Presto Blue viability assay, we determined the half of maximal inhibitory 
concentration (IC50) of DCA, i.e. the concentration of DCA that induces 50% of cell death 
(DCA IC50): 98.6mM for MCF-7/Az, 94.6mM for BT20, 67.3mM for MDA-MB-468, 
66.7mM for SUM149 and 47.4mM for MCF-10A (Figure 6).  
 
 
Figure 6. Breast cancer cell’s viability in response to DCA. Breast cancer cells viability using presto blue 
fluorescence analysis in response to DCA was evaluated in a panel of breast cancer cell lines, including 
MCF-7/Az, BT20, MDA-MB-468 and SUM149, as well as in normal-like MCF10A cells. The concentration of 
DCA that induced 50% of cell death was 98.6mM for MCF-7/Az, 94.6mM for BT20, 67.3mM for MDA-MB-
468, 66.7Mm for SUM149 and 47.4mM for MCF-10A. RFU: Relative Fluorescence Units. 
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We then went to evaluate the response of PDH phosphorylation at Ser 293 following 
DCA exposure, as a measurement of the inactive form of this protein, using western blot 
(Figure 7). We observed that 5mM of DCA was enough to induce a significant decrease 
in pPDH in BT20, SUM149, and MCF-10A cells. In MCF-7/Az breast cancer cells, we 
observed a decrease in pPDH expression with 25, 50 and 75mM of DCA. However, no 
alterations in pPDH levels were observed in MDA-MB-468 breast cancer cells, in any of 
the concentrations and time points used in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. PDH phosphorylation status (Ser293) in response to DCA in breast cancer cell lines. A 
decrease in PDH phosphorylation levels using 5mM of DCA was observed in BT20, SUM149 and MCF-10A 
cells. In MCF-7/Az cells, higher concentrations of DCA (25, 50 and 75mM) were necessary to decrease 
pPDH in these cells. However, no alterations were observed in MDA-MB-468 breast cancer cells, in any of 
the concentrations and time points used in this study. +Stripping from pPDH membrane. 
 
 
 
P-cadherin is usually overexpressed in triple-negative basal-like breast cancer (TN-
BLBC) and presents low expression levels in breast tumors with a luminal-like phenotype 
[71].  
Comparing the levels of P-cadherin expression with the sensitivity to DCA in our panel 
of breast cancer cells, we were able to observe that luminal MCF-7/Az cells, with low 
levels of P-cadherin expression, presented a higher IC50 value and consequently less 
sensitivity to DCA, in comparison with P-cadherin-enriched TN-BLBC MDA-MB-468 and 
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SUM149 cells and normal-like MCF10A cells (Figure 8). However, BT20 cells presented 
both increased P-cadherin levels and increased IC50 (Figure 8).  
 
 
 
 
Figure 8. P-cadherin-enriched breast cancer cells have 
increased sensitivity to DCA. Using Presto Blue 
fluorescence analysis, we observed that TN-BLBC cells, 
namely MDA-MB-468 and SUM149, as well as MCF-10A 
normal-like breast cells, are more sensitive to DCA, in 
comparison with P-cadherin low expressing luminal breast 
cancer cells (MCF-7/Az). However, TN-BLBC BT20 cells 
present high P-cadherin levels and also lower sensitivity to 
DCA 
 
 
 
 
 
These results suggest that breast cancer cells with higher P-cadherin expression present 
increased sensitivity to DCA treatment, while cells with low P-cadherin levels have 
decreased sensitivity to this metabolic modulator, except for BT20 cells. 
 
IIb) P-cadherin expression Modulates pPDH levels in Breast Cancer Cells 
In order to determine if P-cadherin was playing a role in DCA-induced signaling, we then 
went to evaluate the expression of pPDH in P-cadherin manipulated breast cancer cells 
(Figure 9). Thus, we used two different models: a MCF-7/Az luminal breast cancer cell 
model, where P-cadherin was constitutively overexpressed; and the BT20 TN-BLBC cell 
model, with P-cadherin-enriched breast cancer cells, where P-cadherin expression was 
silenced using a specific CDH3 siRNA.  
 
 
 
 
 
 
 
Figure 9. P-cadherin modulates pPDH expression in 
breast cancer cells. Western blot analysis showed an 
increase in pPDH expression levels when P-cadherin is 
overexpressed (MCF-7/Az.P-cadherin), as well as a decrease 
in pPDH expression upon CDH3 downregulation in BT20 
breast cancer cells.   
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Thereby, using western blot analysis, we observed that overexpression of P-cadherin 
(MCF-7/Az.P-cadherin) lead to an increase of pPDH expression, in comparison with 
control cells (MCF-7/Az.Mock) (Figure 9). Accordingly, CDH3 downregulation in BT20 
cells (BT20siCDH3) led to a decrease in the levels of pPDH expression, in comparison 
to BT20 cells transfected with the control siRNA (BT20siCtr) (Figure 9). Thus, these 
results suggest that P-cadherin expression modulates pPDH expression in breast cancer 
cells.   
 
IIc) DCA induces a decrease in P-cadherin expression in Breast Cancer 
Cells 
Since the results above suggest that P-cadherin expression regulates pPDH levels, we 
then went to evaluate if there was a feedback loop and evaluate the effect of DCA on P-
cadherin expression in breast cancer cells. Using western blot analysis, we observed 
that DCA treatment decreases the expression of P-cadherin in a dose-dependent 
manner in MCF-7/Az cells (Figure 10A). On the other hand, in TN-BLBC BT20 cells, 
7.5m of DCA seems to decrease P-cadherin expression (Figure 10B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 10. DCA decreases P-cadherin expression in breast cancer cells. A) Using western blot analysis, 
we observed a decrease in P-cadherin expression with DCA treatment in a dose-dependent manner in MCF-
7/Az breast cancer cells. B) In TN-BLBC BT20 cells, 7.5mM of DCA induces a decrease in P-cadherin 
expression. 
 
Taking together, these results suggest that, DCA probably induces specifically the 
apoptosis of P-cadherin-enriched cells, which lead to the downregulation of its 
expression.  
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IId) P-cadherin expression sensitizes Breast Cancer Cells to DCA-induced 
cell death  
Since the results presented before suggests that P-cadherin-enriched breast cancer 
cells are more sensitive to DCA than the cells with lower P-cadherin expression, and that 
P-cadherin modulates the levels of pPDH in breast cancer cells, we next went to evaluate 
if P-cadherin expression, per se, was being responsible for the sensitivity of these cells 
to DCA in 2D monolayer culture conditions.  
Thus, in order to assess the effect of DCA in MCF-7/Az breast cancer cells with different 
expression levels of P-cadherin, we treated MCF-7/Az.Mock and MCF-7/Az.P-cadherin 
cells with 25 and 50mM of DCA during 24 hours (Figure 11). We were able to observe 
that DCA induced a slight increase in cell death using 25mM and 50mM of this modulator, 
as previously presented above. Interestingly, we also observed that P-cadherin 
overexpressing cells presented a higher decrease in cell viability in comparison with the 
low P-cadherin expressing MCF-7/Az.Mock cells, when these cells were treated with 
25mM of DCA during 24h (Figure 11A). Moreover, P-cadherin overexpressing cells 
present an increase of pPDH expression, either with and without DCA treatment (Figure 
11B). We still observed that in control MCF-7/Az.Mock cells, DCA treatment induces a 
decrease in pPDH expression with both 25 and 50mM in comparison with MCF-
7/Az.Mock non-treated cells (Figure 11B), consistent with the expected effect of DCA in 
pPDH levels. 
In BT20 breast cancer model, CDH3 downregulation induces a slight decrease in the 
viability of these cells, in comparison with BT20siCtr with no treatment or upon 7.5 and 
15mM of DCA during 24 hours (Figure 11C). However, there was no increased 
sensitivity of BT20siCtr to DCA-induced cell death (Figure 11C), as observed in MCF-
7/Az model. Moreover, P-cadherin downregulation was accompanied by a decrease in 
pPDH expression, either with and without DCA treatment. Still, 7.5 and 15mM of DCA 
induced a decrease in pPDH expression when compared with the untreated cells (Figure 
11D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
 
Figure 11. P-cadherin expression sensitizes MCF-7/Az breast cancer cells to DCA-induced cell death. 
In 2D monolayer cell culture conditions, A) P-cadherin overexpression in MCF-7/Az cells presents a higher 
decreased of cell viability in comparison to control cells (MCF-7/Az.Mock cells) when treated with 25mM of 
DCA. B) DCA treatment induces a decrease in pPDH expression with both 25 and 50mM in control cells, 
mainly in MCF-7/Az.mock cells. Moreover, P-cadherin overexpression leads to an increase in pPDH 
expression, either with and without DCA treatment. C) In TN-BLBC BT20 model, CDH3 downregulation 
induces a slight decrease in the viability of these cells, in comparison with BT20siCtr cells. D) With western 
blot analysis, we observed a decrease in pPDH expression with CDH3 downregulation, with and without 
DCA treatment. +Stripping from pPDH membrane. n=3; Kruskal-Wallis test * p≤0.05. (* with no line: relative 
to control cells; * with line: association between line-linked conditions) 
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Since P-cadherin was described to be responsible for self-renewal of BCSCs [101], we 
also evaluated the effect of its expression in the survival of breast cancer cells to DCA-
induced metabolic reprograming using an anchorage-independent culture system, which 
promotes the survival of anoikis-resistant breast cancer cells. Thus, using the both 
previously described breast cancer models, we treated cells with DCA during 24 hours 
and plated the cells in non-adherent conditions for 5 days, promoting the survival of 
anoikis-resistant breast cancer cells (Figure 12).  
In MCF-7/Az luminal model, we observed that P-cadherin overexpression induces an 
increase of self-renewal of these CSCs (Figure 12A). Interestingly, the treatment with 
50mM of DCA induces a decrease in MFE, either in MCF-7/Az.Mock and MCF-7/Az.P-
cadherin cells, being this effect higher in MCF-7/Az.P-cadherin BCSCs (Figure 12A). By 
western blot analysis, we observed an increase in pPDH expression in P-cadherin 
overexpressing cells, either with 25mM of DCA and without DCA treatment, in 
comparison with MCF-7/Az.Mock cells (Figure 12B). 
In TN-BLBC BT20 model, CDH3 downregulation induces a decrease in MFE of BT20 
BCSCs, in comparison to control cells, either without or with 7.5mM of DCA during 24 
hours (Figure 12C).  Interestingly, when the cells were treated with 15mM of DCA, there 
was a high decrease in the number of mammospheres formed in the P-cadherin-
enriched control cells, being this number similar to the one observed in cells with CDH3 
downregulation (Figure 12C). Also, western blot analysis demonstrates a decrease in 
pPDH expression with CDH3 downregulation, with or without DCA, in comparison with 
control cells (Figure 12D). 
Taking together, these results indicate that P-cadherin expression modulates the DCA-
induced anoikis in BCSC. 
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Figure 12. In anchorage-independent conditions, P-cadherin expression sensitizes BCSCs to DCA-
induced cell death. A) P-cadherin overexpression induces an increase of self-renewal in MCF-7/Az BCSCs. 
Interestingly, 50mM of DCA induces a decrease in MFE, either in MCF-7/Az.Mock and in MCF-7/Az.P–
cadherin cells, being the effect higher in BCSCs with increased P-cadherin expression. B) Western blot 
analysis showed an increase in pPDH expression in MCF-7/Az.P-cadherin cells, in comparison with MCF-
7/Az.Mock breast cancer cells. C) The same effect was observed in TN-BLBC BT20 model, where a higher 
decrease in BT20siCtr BCSC survival was observed upon 15mM of DCA, in comparison with BT20siCDH3 
BCSC. D) Western Blot analysis demonstrate a decrease of pPDH expression upon DCA treatment, in 
comparison with non-treated cells, as well as the decrease in pPDH upon CDH3 downregulation, with or 
without DCA, in comparison with the control cells. n=3; Kruskal-Wallis test * p≤0.05; *** p≤ 0.001; **** 
p<0.0001. (* with no line: relative to control cells; * with line: association between line-linked conditions) 
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III. P-CADHERIN EXPRESSION MODULATES THE OXIDATIVE STRESS IN 
BREAST CANCER CELLS 
Our group have described that P-cadherin is responsible for the glycolytic metabolism of 
BCSCs and mediates self-renewal with increased anoikis-resistance [125]. Moreover, it 
is accepted that this type of metabolism promotes lower levels of ROS, potentiating an 
undifferentiated phenotype and promoting a protection from anoikis [26]. Thus, in this 
part of the work, we went to evaluate if P-cadherin was also playing a role in the 
modulation of ROS. To achieve this goal, we used fluorescence-based ROS detection, 
using MitoSOX™ Red reagent, a fluorogenic dye that detects mitochondria derived 
superoxide anion in live cells. 
We observed an alteration from a more pronounced peri-nuclear staining in BT20siCtr, 
to a spread pattern of mitochondrial derived ROS staining in BT20siCDH3 cells (Figure 
13A). This shift was confirmed by the increase of the MitoSOxRed intensity in 
BT20siCDH3 cells, in comparison with BT20siCtr cells (Figure 13B), specifically 
measured in the membrane region between adjacent cells.  
 
 
 
 
Figure 13. CDH3 silenced TN-BLBC BT20 cells increases levels of mitochondrial derived ROS, 
namely superoxide anion. A) MitoSoxRed immunofluorescence of BT20 breast cancer cells with CDH3 
silencing demonstrates an increase and cytoplasmic spread of mitochondrial ROS, in comparison with the 
control cells. B) Internuclear fluorescence profiles of MitoSOX™ Red in TN-BLBC BT20 cells confirms the 
decrease in superoxide anion measured by MitoSOX™ Red immunofluorescence in comparison with the 
control cells. n=1. [immunofluorescence: DAPI (blue), MitoSoxRed (red), P-cadherin (green)]. 
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Moreover, when cells were treated with DCA, we observed an increase of mitochondrial 
ROS, in comparison with the non-treated cells (Figure 14). Moreover, we were also able 
to observe the above described increase in mitochondrial ROS in CDH3 silenced cells, 
whether treated or non-treated with DCA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Mitochondrial ROS are increased upon CDH3 downregulation and DCA treatment in TN-
BLBC BT20 cells. DCA increases mitochondrial ROS in BT20 breast cancer cells. Moreover, our results 
show an increase in red fluorescence in CDH3 downregulated cells, with or without DCA treatment. n=1 
[immunofluorescence: DAPI (blue), MitoSoxRed (red)]. 
 
 
Although preliminary, our results show that P-cadherin silencing increases mitochondrial 
derived ROS production, suggesting that P-cadherin acts as a survival factor through the 
modulation of oxidative stress. 
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CHAPTER V 
DISCUSSION 
 
The results presented in this work provide novel insights about the role of P-cadherin in 
metabolic pathways, through the regulation of pPDH expression in breast cancer cells, 
as well as the possible clinical implications of P-cadherin expression in the response of 
breast cancer cells to DCA treatment.   
 
Breast cancer is a heterogeneous disease with different biological behaviors, being 
divided into five distinct subtypes, according to different signatures and clinical 
outcomes, namely luminal A, luminal B, normal breast-like, HER-2 overexpressing and 
basal-like [51]. Over the past few years, our group has been describing several detailed 
functions of P-cadherin in breast cancer, a molecule which expression is differentially 
enriched in BLBC. These tumors are TNBC [127], associated with an aggressive 
behavior and worst patient prognosis [128, 129]. In this way, BLBC are characterized by 
the lack of ER and PgR, as well as the lack of HER-2 overexpression [130], which result 
in the resistance to anti-hormone therapies and HER-2 target therapies [131]. 
Histologically, BLBC are poorly differentiated carcinomas, present high nuclear and 
histological grade and frequently show medullary and metaplastic features, being the 
triple negative phenotype along with positivity for CK5 and/or EGFR the most suitable 
immunohistochemical criterion to identify these tumors [52, 132]. Interestingly, it has 
been reported that clinical features of breast tumors are reflections of specific 
glycometabolic pathways, attributing different metabolic behaviors to breast cancer 
molecular subtypes [133], which might contribute to a better orientation for clinical 
treatment [133]. Specifically, it has been described that BLBC present a stronger 
response to hypoxia, as well as a higher glycolytic metabolism than tumors with luminal 
characteristics, expressing hypoxic, glycolytic and acidosis markers, such as HIF-1α, 
GLUT1, CAIX, among others [55, 134]. Moreover, Dong et al. showed that the 
overexpression of PKM2, an important protein to control cell metabolism; glutamine-
fructose-6-phosphate transaminase 1 (GFPT1), the first enzyme of hexosamine 
biosynthetic pathway; as well as G6PD, the first enzyme of PPP, were associated with 
poor prognosis of TNBC, as well as with worse response rate in neoadjuvant 
chemotherapy-treated breast cancer [133]. Interestingly, our group demonstrated that 
aberrant P-cadherin expression, a poor prognostic factor in breast cancer and a marker 
of BLBC, is associated with the hypoxic/glycolytic and acid resistant phenotype in breast 
cancer [125].  
45 
 
There are strong evidences that reversing the glycolytic metabolic behavior of cancer 
cells is a promising strategy that may offer a relative selectivity to target cancer cells [9]. 
Based on this concept, it has been described that DCA, by inhibiting PDK, decreases 
tumor growth in many cancer types, including breast cancer [39]. PDC is constituted by 
PDH and its regulatory proteins: PDK, which inhibits PDH by phosphorylation; and 
pyruvate dehydrogenase phosphatase (PDP), that activates PDH by dephosphorylation 
[135]. The phosphorylation of E1 subunit of PDH occurs at three specific serine residues, 
namely Ser 293 (site 1), Ser 300 (site 2) and Ser 232 (site 3) [136]. There are four PDK 
isoforms (1, 2, 3, 4), which differ in their intrinsic activity of PDH phosphorylation, tissue 
distribution, as well as in their sensitivity to the selective inhibitor drug, DCA [135]. 
Interestingly, each PDK isoforms is activated in response to different intracellular and 
extracellular conditions [137]. For instance, it has been demonstrated that liver-
metastatic cells displayed increased HIF-1α, as well as increased PDK1, being this PDK 
isoform required for efficient liver metastasis in breast cancer patients [138]. Moreover, 
PDK2 is activated by acetyl-CoA and NADH, and inhibited by ADP (adenosine 
diphosphate); PDK3 is activated by ATP; and PDK4 is activated transcriptionally by 
hormonal signals, such as retinoic acid and glucocorticoids, being transcriptionally 
repressed by insulin [137].  
There are only a few reports exploring the association of PDK isoforms with clinical and 
molecular features of breast cancer. Choi et al. studied the expression of several 
metabolism-related proteins such as GLUT-1, CAIX, PDK1, HIF-1α, among others, 
according to breast cancer molecular subtype, and found that PDK1 was not significant 
correlated with molecular subtypes of breast cancer [139].  
 
In this work, we showed a positive correlation between P-cadherin and PDK1, as well as 
with PDHA1, in breast cancer samples database analysis. This finding is consistent with 
a CCLE analysis, showing increased expression of PDK1 in TNBC cell lines, specifically 
BT20 and MDA-MB-468 cells (data not shown). 
It is described that, under hypoxia, HIF-1α activates PDK1 in order to direct pyruvate 
away from the mitochondria, to reduce mitochondrial oxygen consumption and decrease 
ROS production, helping cells to adapt to the hypoxic environment caused by oxygen 
deprivation [140]. In accordance, HIF-1α also induces an increase of membrane P-
cadherin expression in breast cancer cells [125], as well as a reduction of ER, a known 
CDH3 repressor [141].  
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Despite the fact that all four PDKs are able to phosphorylate PDH in vitro, PDK2 has the 
greatest activity to phosphorylate site 1, the most rapid and well-known mechanism for 
PDH inactivation, followed by PDK4, PDK1 and PDK3 [142]. Although PDK2 is 
ubiquitously expressed in different human tissues, while the other isoforms present 
tissue-specific distribution [42], this isoform is the most sensitive to pyruvate analog 
molecule, DCA [142]. Moreover, Sutendra et al. showed that DCA inhibit both PDK2 
activity and HIF-1α in mammary carcinoma cells and that this isoform is associated with 
poor prognosis in breast cancer [143].  
Through bioinformatic analysis (data not shown), we also observed an increased 
expression of PDK1 isoform, and a slight increase of PDK3 expression in ER negative 
breast cancer samples, in comparison with ER positive group. In contrast, PDK2 and 
PDK4 isoforms were increased in ER positive than in ER negative breast cancer. Still, 
we found that PDHA1 presented an increased expression in ER negative breast cancer. 
We also observed a variability between the expression of the four PDK isoforms, as well 
as PDHA1 gene in the breast cancer cell lines.  
Despite the bioinformatic data presented and discussed in this work about PDK and 
PDH, nothing more is known about the association between P-cadherin and the 
expression of these key metabolic proteins in breast cancer.  
 
 
P-CADHERIN-ENRICHED BREAST CANCER CELL LINES PRESENT 
INCREASED SENSITIVITY TO DCA 
In the last decade, there is an increased recognition that metabolic reprograming is a 
result of an adaptation of cancer cells to environmental pressures. In this way, the 
upregulation of glycolysis and resistance to acid-induced apoptosis are cellular 
adaptations which support the proliferation and survival of cancer cells. Interestingly, it 
has been described that this cancer-specific metabolic remodeling can be reversed by 
DCA, in which by inhibiting PDK activity, leads to a reactivation of PDH, promoting the 
shift from glycolysis to oxidative metabolism [38, 40, 41]. Furthermore, it is described 
that DCA-induced metabolic reprograming occurs preferentially in glycolytic cancer cells, 
leading to a more oxidative phenotype and decreasing proliferation, while oxidative cells 
remain less sensitive to DCA treatment [43]. Currently, there are 7 clinical trials that 
studies the potential anticancer effect of DCA, including one specifically in breast cancer 
(clinicaltrials.gov). Despite that, the responses of cancer cells to DCA treatment have not 
been fully elucidated [38]. 
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In this work, we demonstrate that TN-BLBC (MDA-MB-468 and SUM149) cells, as well 
as MCF-10A normal-like breast cells, are more sensitive to DCA, presenting lower DCA 
IC50 values, than luminal breast cancer cells. These results are in accordance with 
previous reports showing that TNBC cells are more glycolytic than luminal breast cancer 
cells [144], being more sensitive to DCA metabolic reprograming. Interestingly, since P-
cadherin expression is enriched in TN-BLBC, our results also demonstrated that the cells 
with increased sensitivity to DCA were the ones presenting higher levels of P-cadherin 
expression. However, although BT20 breast cancer cells present high P-cadherin 
expression, these cells were the less sensitive to DCA induced cell death, in comparison 
with the others TN-BLBC cell lines used in this study. This result can be explained based 
on the preliminary and non-published observation from our group, where BT20 cells 
present a more oxidative behavior, similar to low P-cadherin expressing MCF-7 breast 
cancer cells, when compared with MDA-MB-468 and SUM149 breast cancer cell lines. 
Moreover, in order to evaluate the efficacy of DCA in inhibiting PDK activity, we also 
evaluated the expression of the inactive form of PDH, pPDH, in our panel of breast 
cancer cell lines. Thereby, we demonstrated that 5mM of DCA is enough to induce a 
decrease in pPDH expression in BT20, SUM149, and MCF-10A cells. This is in 
accordance with the CCLE data, where we observed that BT20 breast cancer cell line 
present high levels of the most DCA sensitive isoform, PDK2. On the other hand, a higher 
DCA concentration is needed (25mM) in luminal MCF-7/Az breast cancer cells, in order 
to decrease pPDH levels, which is in line with their preferential oxidative behavior. 
Furthermore, MDA-MB-468 cells was the only breast cancer cell line with no alterations 
in pPDH levels induced by DCA, in accordance to their low PDK2 and high PDHA1 
expression levels from CCLE analysis. 
 
 
P-CADHERIN EXPRESSION MODULATES THE EXPRESSION OF pPDH IN 
BREAST CANCER CELLS 
BLBC present a glycolytic metabolism, expressing hypoxic and glycolytic markers [53, 
145]. Also, the constitutive upregulation of glycolysis is likely to be a cellular adaption to 
hypoxic conditions in these tumors [35]. In this context, our group demonstrated, for the 
first time, the link between aberrant P-cadherin expression, a biomarker of BLBC, and 
the metabolic behavior of breast cancer cells [125]. In this report, P-cadherin expression 
is shown to be significantly associated with the expression of HIF-1α, GLUT1, CAIX, 
MCT1, as well as CD147 in human breast carcinomas [125]. Moreover, HIF-1α 
stabilization is accompanied by increased membrane P-cadherin expression, and that 
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the breast cancer cell fractions harboring high levels of P-cadherin are the same 
exhibiting a glycolytic and acid-resistant phenotype, presenting high amounts of GLUT1 
and CAIX [125]. However, nothing more is known about the signaling between this 
adhesion molecule and the key metabolic proteins in breast cancer cells. 
 
In this work, we observed that P-cadherin modulates the expression of the inactive form 
of PDH, pPDH. Specifically, we observed that overexpression of P-cadherin leads to an 
increase in expression of pPDH in these cells, either in 2D monolayers, as well as in 
anchorage-independent conditions. The increase of pPDH levels leads to a decrease in 
the flux of pyruvate into the TCA cycle, decreasing the respiration rate and possibly, a 
consequent increase of the glycolytic behavior of cells [39]. This result is not only in 
accordance with previous publications of our group showing that P-cadherin 
overexpression is associated with a glycolytic metabolism in breast cancer cells [125], 
but also with our unpublished data, where we observe that P-cadherin silencing 
decreases the extracellular acidification rate, a readout of a glycolytic impairment, in 
breast cancer cells. Moreover, we also observed a decrease in P-cadherin expression in 
MCF-7/Az cells induced by DCA, which might be due to the metabolic reprograming 
towards respiration, leading to a decrease in P-cadherin-enriched glycolytic cells. 
However, further studies are needed to evaluate if the alterations in PDH activity induces 
metabolic alterations that consequently decrease P-cadherin expression or whether it 
induces a direct effect in P-cadherin expression. 
 
Furthermore, our group also demonstrate that breast cancer cells with increased P-
cadherin expression, presenting a highly glycolytic behavior, is associated with 
increased cell motility, migration and invasion capacity [117, 118]. These cells present 
increased membrane transporters, namely CAIX and MCTs, in order to maintain pH 
homeostasis within the cells, inducing extracellular acidification. This acidification is 
known to facilitate in vitro cancer cell invasion and in vivo metastization [146]. 
 
Taking together, we demonstrate for the first time that P-cadherin expression modulates 
the levels of pPDH, which might be the mechanism responsible for the metabolic activity 
of this cell adhesion molecule in breast cancer cells. Still, since DCA induced a decrease 
in P-cadherin expression, we hypothesize that this metabolic modulator would also play 
a role in the impairment of aggressive properties mediated by P-cadherin expression in 
breast cancer cells. 
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P-CADHERIN EXPRESSION AS A VALUABLE BIOMARKER TO PREDICT THE 
RESPONSE TO DCA TREATMENT IN BREAST CANCER 
Increasing body of evidences have been demonstrating that reversing the glycolytic 
metabolic behavior of cancer cells could be a promising strategy to target cancer cells in 
a selective way [9]. Accordingly, by inhibiting PDK, and consequently the activation of 
PDH, promoting OXPHOS in these cells, DCA decreases tumor growth in many cancer 
types, including breast cancer [39]. DCA-induced metabolic reprograming was already 
shown to eliminate preferentially BCSCs both in vitro and in vivo [80], suggesting that 
the decreased activity of PDH is responsible for the glycolytic behavior of BCSCs [80].  
 
In this work, we demonstrate that P-cadherin expression modulates the sensitivity of 
BCSCs to DCA-induced cell death. We specifically showed that the silencing or the 
overexpression of P-cadherin, either decreases or increases, respectively, the sensitivity 
of BCSCs to DCA-induced breast cancer cells.  
P-cadherin promotes stem-like properties to breast cancer cells and is recognized as a 
BCSC marker, being associated with the expression of CSC markers, such as CD44, 
CD49f and ALDH1 [101]. Although the reports about the metabolic behavior of cancer 
stem cells are increasing exponentially, there is still no consensus about their metabolic 
behavior. Some authors claim that normal and cancer cells with stem like properties use 
preferentially glycolysis over OXPHOS as their main source of energy [147, 148]. 
Specifically, there are reports showing that BCSCs present a glycolytic behavior, with 
higher ratio of lactate production to oxygen consumption, higher glucose consumption, 
as well as fewer and less active mitochondria than non-BCSCs [80, 82, 83]. Moreover, 
the use of metabolic modulators as a search for therapeutic applications against BCSC 
are being widely used also to demonstrate the glycolytic behavior of these cells [81]. For 
instance, Ciavardelli et al. demonstrated that treatment with 2-DG, an inhibitor of 
glycolysis, inhibits BCSCs proliferation, presenting a synergistic effect in BCSC death 
when in combination with doxorubicin [81].  
In contrast, other authors claim that BCSCs present an increased OXPHOS behavior, 
with increased mitochondrial mass and mitochondrial functional activity [84-89]. 
Furthermore, Hirsch et al. described that the combination of metformin, a mitochondrial 
inhibitor of complex I, and doxorubicin kills BCSCs, as well as non-stem cancer cells in 
culture, reduces tumor mass and prolongs remission in a more effective manner than 
each drug alone [93]. Also, targeting BCSCs with atovaquone, a selective inhibitor of 
OXPHOS, induces apoptosis in these cancer cells population [92]. 
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In this work, we demonstrate that, in 2D monolayer culture conditions, MCF-7/Az.P-
cadherin breast cancer cells present higher levels of cell death when treated with two 
different concentrations of DCA, in comparison with the control MCF-7/Az.Mock cells. 
Moreover, in BT20 breast cancer model, CDH3 downregulation presents increased 
resistance to DCA induced cell death. Interestingly, these results were more pronounced 
when the cells were cultured in anchorage-independent conditions, in both breast cancer 
models. In anchorage-independent conditions, we observed an increase of self-renewal 
in P-cadherin-overexpressing cells, MCF-7/Az.P-cadherin and BT20siCtr, in comparison 
with the respective low P-cadherin-expressing counterparts, MCF-7/Az.Mock and 
BT20siCDH3 cells. These results are in accordance with described P-cadherin’s anoikis-
promoting role previously reported by our group, where we demonstrate that P-cadherin-
enriched breast cancer cell populations have increased ability to survive in anoikis 
promoting conditions [101]. Interestingly, we observed a decrease in MFE, when MCF-
7/Az cells were treated with 50mM of DCA, being this effect higher in P-cadherin-
enriched MCF-7/Az cells than in MCF-7/Az.Mock cells. The same results were observed 
in BT20 model, where 15mM of DCA induced a higher decrease in the number of 
mammospheres formed in BT20siCtr cells, with high P-cadherin levels, in comparison 
with P-cadherin-silenced BT20 cells. Taking together, we demonstrate that the silencing 
of P-cadherin expression decreases the sensitivity of BCSCs to DCA-induced cell death, 
which suggests that P-cadherin enrichment dictates sensitivity of BCSCs to DCA-
induced metabolic reprograming.  
The effect of P-cadherin in the sensitization of DCA-induced breast cancer cell death 
being potentiated in anchorage-independent conditions can be explained by PDK 
modulation, as well as to the alterations in metabolic properties induced by these 
conditions. It is reported that untransformed human mammary cells are able to 
upregulate the expression of PDK upon matrix detachment [28]. Thus, cell detachment 
reprograms cells to rely on glycolysis by attenuating the flux of glycolysis-metabolites 
into mitochondrial oxidation. Importantly, altered glucose metabolism is a crucial factor 
in the modulation of anoikis sensitivity, in which decreased glucose oxidation confers 
anoikis resistance. Therefore, due to the Warburg effect, cancer cells have survival 
advantage in anchorage-independent conditions [28]. Thus, metabolic reprograming 
induced by DCA can restore cancer cells sensitivity to anoikis in matrix detachment 
conditions, impairing the metastatic potential of breast cancer cells in circulation.  
The breast cancer heterogeneity is, among other factors, reflected in the metabolic 
behavior of cell population and their plasticity. However, there are reports describing that 
DCA-induced metabolic reprograming occurs preferentially in glycolytic cancer cells [43].  
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Accordingly, our results reinforce the role of P-cadherin as an inducer of glycolytic 
behavior of breast cancer cells, since P-cadherin-enriched cell populations are more 
sensitive to DCA. Furthermore, the enhanced effect of DCA observed in anchorage 
independent conditions, where BCSCs are selected, suggests that these BCSCs present 
preferentially a glycolytic behavior. 
 
Thus, since our results shows that P-cadherin expression modulates PDH activity in 
breast cancer cells and, consequently, the metabolic behavior of cells, we hypothesize 
that P-cadherin overexpressing breast carcinomas, with stem-like properties and 
increased glycolytic behavior, would present better response to DCA induced metabolic 
reprograming and cell death. For this reason, we also hypothesized that P-cadherin 
expression in breast cancer might be a valuable biomarker to predict the response to 
DCA treatment in this type of cancer.  
 
 
CDH3 DOWNREGULATION INCREASES MITOCHONDRIAL ROS IN TN-
BLBC BT20 CELLS 
ROS include several oxygen-containing molecules, with inherent chemical properties 
that confer reactivity to different biological targets [149]. Interestingly, in the last two 
decades, it has been described that ROS have double-faced role, since it drives 
proliferation, as well as apoptosis in cancer cells [150]. At early stages of cancer 
development, the antioxidant activity decreases and ROS promotes cancer initiation 
through the induction of DNA damage and genomic instability. On the other hand, at late 
stages, tumor cells increase their intracellular antioxidant systems, such as NADPH and 
glutathione, escaping to oxidative stress-induced apoptosis [151]. Therefore, in order to 
an antioxidant strategy be effective in cancer treatment, it must target ROS when they 
promote proliferation rather than apoptosis, i.e. early stage of the disease.  
In addition to being highly proliferative, cancer cells are resistant to anoikis, a type of 
apoptotic cell death caused by the detachment of cells from the ECM. [28]. With the 
metabolic alterations caused by the Warburg effect, cancer cells have the advantage to 
avoid the production of excess ROS and overcome anoikis. Moreover, increased aerobic 
glycolysis also increase the glucose flux into the PPP, which is a major pathway to 
produce NADPH, a cellular antioxidant that protects cells against the oxidative stress. 
Taking together, by enabling cancer cells to avoid the overproduction of ROS and 
increasing their antioxidant systems, the Warburg effect maintains the redox 
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homeostasis, as well as it promotes resistance to oxidative stress induced anoikis and, 
subsequently, metastatic spread of cancer cells [152, 153]. 
 
In this work, we demonstrate an increase in mitochondrial derived ROS levels upon 
CDH3 downregulation in TN-BLBC BT20 cells. This finding is in accordance with 
preliminary data from our group, showing that P-cadherin expression modulates 
oxidative stress in breast cancer cells, namely ROS levels, through the regulation of 
SOD1 and SOD2 expression and activity. Moreover, these results are also in accordance 
with the low levels of ROS and antioxidant systems described in BCSCs, where P-
cadherin is known to play a role in the maintenance of their self-renewal [81, 82, 101]. 
Thus, some authors claim that normal and cancer cells with stem-like properties exhibit 
increased adaptation to oxidative stress, with enhanced antioxidant protective systems 
and low levels of ROS [147, 148]. It is known that breast cancer cells, including BCSCs, 
present increased antioxidant defenses and low levels of ROS, allowing them to escape 
to oxidative stress induced anoikis [47, 80]. Diehn et al. observed that normal mammary 
epithelial stem cells, as well as BCSCs, present lower levels of ROS when compared 
with their corresponding mature progeny cells and non-tumorigenic cells, respectively 
[26]. 
Some chemotherapeutic agents, as well as radiotherapy, induces cancer cell death, in 
part, by the production of free radicals [154]. In this context, Phillips et al. showed that 
BCSCs are a radio-resistant subpopulation of breast cancer cells, which increase in 
number after short courses of fractionated irradiation [29]. Thus, the rapid repopulation 
of cancer cells observed during gaps in radiotherapy might be due to the presence of 
CSCs, which could be responsible for recurrence, metastasis and therapeutic resistance 
[29]. In this way, it is possible that the therapeutic resistance presented by these cells 
might be mediated by their increased capacity to overcome intracellular oxidative stress 
levels [155]. 
 
In this work, we were also able to observe that BT20siCtr cells present a pronounced 
peri-nuclear staining, while BT20siCDH3 cells present a more spread pattern of 
mitochondrial ROS staining. Since it is known that P-cadherin is involved in the 
maintenance of stem-like properties in BCSCs, as well as it is associated with the 
expression of CSC markers, such as CD44, CD49f and ALDH1 [101], this result is in line 
with reports suggesting that peri-nuclear mitochondrial arrangement is an indicator of 
stemness [156-158]. 
Finally, our findings also suggest that P-cadherin acts as survival factor [119], due to its 
role in the modulation of oxidative stress. Since ROS are generated mainly as a 
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byproduct of OXPHOS, through the incomplete reduction of oxygen, and DCA promotes 
the entrance of pyruvate into the TCA and subsequently its mitochondrial oxidation [40], 
this drug promotes the production of mitochondrial derived ROS. The production of these 
ROS can ultimately trigger caspase activation and apoptosis through the release of 
cytochrome c and other pro-apoptotic proteins [159]. Accordingly, Sutendra et al. 
demonstrated that DCA decrease mitochondrial membrane potential and increase 
mitochondrial ROS, PDH activity, as well as mitochondrial respiration in mammary 
carcinoma cells [143]. In this work, we observed an increase in mitochondrial derived 
ROS upon DCA treatment in comparison with non-treated cells, whether with and without 
CDH3 downregulation. Since the immunofluorescence analysis is not a quantitative 
technique, these results need to be further quantified and validated. 
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CHAPTER VI 
CONCLUSIONS  
 
The results presented and discussed in this work allowed us to conclude that: 
 
1. Breast cancer cell lines enriched for P-cadherin are more sensitive to DCA-
induced metabolic reprograming and cell death than the ones with low P-cadherin 
expression levels, probably due to their increased glycolytic behavior. Using 
Presto Blue fluorescence analysis, we were able to demonstrate that P-cadherin-
enriched breast cancer cell lines present a lower DCA IC50 value in comparison with the 
ones expressing low levels of this adhesion molecule.  
 
2. P-cadherin expression modulates the expression of pPDH in breast cancer 
cells. Using Western blot analysis, we showed that P-cadherin expression increases the 
levels of pPDH, the inactive form of PDH, and, in contrast, P-cadherin downregulation 
decreases pPDH expression, either with and without DCA treatment.  
 
3. P-cadherin expression sensitizes breast cancer cells to DCA-induced 
BCSC anoikis. Through the MFE assay in anchorage independent conditions, we 
observed that breast cancer cells with increased P-cadherin expression have a higher 
response to DCA-induced cell death than the ones with low P-cadherin expression. 
Therefore, we hypothesized that P-cadherin expression might be a valuable biomarker 
to predict the response to DCA treatment in breast cancer patients. 
 
4. P-cadherin downregulation induces an increase of mitochondrial derived 
ROS production in TN-BLBC BT20 cells. Therefore, we hypothesized that P-cadherin 
is a survival factor in breast cancer cells probably due to its role in the regulation of 
oxidative stress in these cells.  
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CHAPTER VII 
PROPOSED MODEL 
 
P-cadherin-enriched breast cancer cells are more likely to present a glycolytic and acid 
resistant phenotype [125], being enriched in glycolytic transporters, such as GLUT1, 
allowing the entrance of glucose into the cells, which is then converted into lactate, and 
transported for the extracellular medium by MCT1 transporter [53]. In order to maintain 
the intracellular pH, CAIX is upregulated as well in these cells, contributing for cancer 
cell survival [54]. Moreover, preliminary data from our group suggest that P-cadherin 
expression plays a role in the modulation of oxidative stress, by increasing the 
expression and activity of scavenging systems, such as SOD1 and SOD2, respectively, 
decreasing the levels of ROS in BCSCs (Figure 15).  
In this work, we demonstrate for the first time that P-cadherin has a role in the modulation 
of PDH levels in BCSCs, by increasing the inactive form of this protein, pPDH, 
contributing for the glycolytic behavior, as well as for the survival of these cells. Thereby, 
and since DCA-induced metabolic reprograming occurs preferentially in glycolytic cancer 
cells [43], the treatment of BCSCs with DCA, an inhibitor of PDK, activates PDH and 
reverses the glycolytic phenotype of these cells, by increasing their mitochondrial 
function and, consequently, the production of mitochondrial ROS, decreasing the 
survival of BCSCs (Figure 15).  
 
 
 
 
 
 
 
 
 
Figure 15. Schematic representation of the proposed model of this work. P-cadherin has a role in the 
modulation of PDH levels, by increasing the inactive form of this protein, contributing for the glycolytic 
behavior, as well as for the survival of BCSCs. When these cells are treated with DCA, PDK is inhibited, 
activating PDH and cells rely on oxidative phosphorylation, increasing the production of ROS and decreasing 
the survival of BCSCs.  
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CHAPTER VIII 
FUTURE PERSPECTIVES 
 
In the last few years, several oncogenic effects have been attributed to P-cadherin 
expression in a breast cancer context. Importantly, this molecule plays a role as a 
metabolic modulator, a new emerging hallmark of cancer. This work reinforces the role 
of P-cadherin as a metabolic modulator, as well as describes for the first time this 
molecule as a biomarker of the response of DCA-induced metabolic reprograming, 
through its ability to modulate PDK/PDH signaling. Although some data needs to be 
further validated, this work raises many interesting questions and challenges that remain 
to be elucidated. Thus, additional questions should be addressed in future studies:  
 
1. Understand the combinatory effect of DCA-induced metabolic reprograming with 
oxidative stress induced by a chemotherapeutic agent widely used for breast cancer 
treatment, such as doxorubicin. 
 
2. Evaluate the role of P-cadherin as a biomarker of resistance to oxidative stress 
induced by chemo- and radio-therapy in breast cancer cells. 
 
3. Validate the in vitro findings described in this work, using in vivo models.  
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